Prevalence of anti-ulcer drug use in a Chinese cohort

Table 1 Age distribution of patients receiving anti-ulcer drugs and age-specific prevalence of anti-ulcer drug use from 1997 to 2001

	1997	1998	1999	2000	2001	1997-2001
Sampling cohort
0 – 19 years	57388	56427	55448	54684	51029	52103
20 – 39 years	62613	63765	64848	65219	63800	69425
40 – 59 years	39809	41420	42922	44241	45432	47663
60 years and older	20971	21836	22489	23093	23715	26780
Total	180781	183448	185707	187237	183976	195971
Patients with anti-ulcer drugs
0 – 19 years	2965	3611	5171	4634	4712	12339
20 – 39 years	5345	6741	9249	8788	9673	23741
40 – 59 years	4933	6213	8277	8113	8664	20166
60 years and older	4172	4787	5905	5643	6132	14483
Total	17415	21352	28602	27178	29181	70729
Prevalence of anti-ulcer drug use
0 – 19 years	5.2%	6.4%	9.3%	8.5%	9.2%	23.7%
20 – 39 years	8.5%	10.6%	14.3%	13.5%	15.2%	34.2%
40 – 59 years	12.4%	15.0%	19.3%	18.3%	19.1%	42.3%
60 years and older	19.9%	21.9%	26.3%	24.4%	25.9%	54.1%
Total	9.6%	11.6%	15.4%	14.5%	15.9%	36.1%

Table 2 Recipients of anti-ulcer drugs by main ingredient from 1997 to 2001 (number of new users in parentheses)

ATCa coding	Group/ingredient name	1997	1998	1999	2000	2001	1997-2001
A02BA H2 RA
	01 Cimetidine	11538	15793 (11340)	22905 (14525)	22356(10564)	24305 (9667)	57634
	02 Ranitidine	1588	1852 (1482)	2262 (1757)	2283 (1611)	2579 (1802)	8240
	03 Famotidine	974	1143 (953)	1401 (1113)	1526 (1216)	1669 (1232)	5488
	04 Nizatidine	187	255 (221)	295 (236)	199 (157)	137 (108)	909
	06 Roxatidine	89	98 (82)	87 (76)	83 (67)	97 (80)	394
A02BB Prostaglandins
	01 Misoprostol	128	145 (129)	156 (135)	150 (112)	88 (68)	572
A02BC PPIS
	01 Omeprazole	709	913 (807)	1168 (990)	1150 (917)	1445 (1156)	4579
	02 Pantoprazole	-	1(1)	84 (84)	147 (133)	273 (255)	473
	03 Lansoprazole	151	391 (365)	531 (459)	647 (537)	785 (643)	2155
	04 Rabeprazole	-	-	-	-	31 (31)	31
A02BX Other drugs
	01 Carbenoxolone	287	260 (219)	337 (271)	155 (105)	199 (164)	1046
	02 Sucralfate	3463	3192 (2510)	3107 (2301)	2390 (1506)	2173 (1390)	11170
	03 Pirenzepine	1177	1197 (937)	1181 (857)	731 (454)	625 (351)	3776
	05 Bismuth subcitrate	329	299 (266)	271 (223)	173 (141)	142 (111)	1070
	06 Proglumide	113	61 (53)	36 (34)	3 (3)	8 (5)	208
	07 Gefarnate	248	295 (270)	416 (363)	326 (265)	203 (161)	130 7
	- Cetraxate	356	101 (81)	72 (59)	48 (40)	41 (37)	57 3
	- Urogastrone	192	46 (34)	42 (32)	14 (12)	6 (5)	275
Total		17415	21352 (14423)	28602(16611)	27178(11660)	2918123(10622)	70729

^aATC = Anatomical therapeutic chemical classification system.

Table 3 Total prescribed amount of anti-ulcer drugs by main ingredient from 1997 to 2001 (unit of measurement: numbers of defined daily doses [DDDs])

ATCa coding	Group/ingredient name	1997	1998	1999	2000	2001
A02BA H2 RA
	01 Cimetidine	114145	151403	221528	198255	221836
	02 Ranitidine	57329	62357	69780	69954	88034
	03 Famotidine	33366	40063	51198	52852	53108
	04 Nizatidine	8943	12304	12282	8269	5305
	06 Roxatidine	3493	3057	3215	2847	4460
A02BB Prostaglandins
	01 Misoprostol	2244	3649	5594	4534	1941
A02BC PPIS
	01 Omeprazole	26635	33587	46429	43589	57193
	02 Pantoprazole	-	14	2593	4845	9276
	03 Lansoprazole	5840	14276	19624	24860	31023
	04 Rabeprazole	-	-	-	-	864
A02BX Other drugs
	01 Carbenoxolone	5708	4164	4768	1945	1918
	02 Sucralfate	26172	20170	15942	10960	9898
	03 Pirenzepine	7575	7378	5925	3868	3942
	05 Bismuth subcitrate	7999	6104	5213	2686	2754
	06 Proglumide	1010	459	198	12	31
	07 Gefarnate	14379	17859	26568	16682	8972
	- Cetraxate	4072	1254	849	615	657
	- Urogastrone	5067	1272	1151	232	32
Total		323976	379370	492856	447005	501243
	Ambulatory sector	297213	355837	465326	420144	470924
	Inpatient sector	26764	23532	27530	26861	30319
DDDs/1000 inhabitants/day		4.9	5.7	7.3	6.5	7.5

^aATC = Anatomical therapeutic chemical classification system.